The COVID-19 epidemic has had a huge impact on the world. Researchers are desperately searching for an effective treatment for COVID-19. In December 2021, FDA authorized Paxlovid (nirmatrelvir and ritonavir) for the treatment of mild-to-moderate COVID-19. Paxlovid is now widely available in community pharmacies. 

Paxlovid significantly reduced the proportion of people with COVID-19 related hospitalization or death from any cause by 88% compared to placebo among patients treated within five days of symptom onset and who did not receive COVID-19 therapeutic monoclonal antibody treatment.

"Paxlovid is a blockbuster drug for the treatment of COVID-19. In response to this trend, our management decided to launch a new product line offering the intermediate caronic anhydride and other key intermediates of Paxlovid at the most reasonable price," said the marketing director of Huateng Pharma," Previously, we have been a trusted CDMO for pharmaceutical intermediates, offering custom synthesis and scale-up services for many years. We are confident that our relationship with our partners will be further strengthened with the launch of this popular pharmaceutical intermediate."

With its state-of-the-art facilities, Huateng Pharma has the capabilities to perform process development and scale-up antiviral drug intermediates. Our chemists have many years of experience in the industry and have specialised in the development of synthetic routes to complex organic molecules used in preclinical studies.

Huateng Pharma has the knowledge and facilities to develop and optimize existing processes or design new synthetic routes with fewer steps and increased atom efficiency, improving yields and reducing costs. Using its in-house facilities and talented chemists, Huateng Pharma can scale up to 10kg or outsource larger quantities to trusted partners.

With any interest in Huateng Pharma, please visit https://us.huatengsci.com/.

About Huateng Pharma

Huateng Pharma is a global provider in contract development and manufacturing for anti-viral drug intermediates.  With our focus on operational excellence and the integration of manufacturing operations with EHS, quality assurance, quality control, regulatory, supply chain management and project management, we can manufacture, scale-up and supply high-quality intermediates and APIs from our China facility.